What is Ionpath?
Ionpath is a pioneer in high-definition spatial proteomics, specializing in Multiplexed Ion Beam Imaging (MIBI). By overcoming the inherent limitations of traditional immunohistochemistry, the company enables researchers to visualize and quantify the tissue microenvironment with unprecedented resolution. This technological edge is critical for organizations operating in immuno-oncology, immunology, and neuroscience. Through the integration of advanced pathology and data science, Ionpath delivers actionable insights that accelerate medical discovery and improve patient outcomes. Their platform serves as a cornerstone for pharmaceutical and biotechnology firms seeking to understand the spatial architecture of disease at the single-cell level.
How much funding has Ionpath raised?
Ionpath has raised a total of $20M across 3 funding rounds:
Debt
$1M
Series B
$18M
Debt
$1M
Debt (2020): $1M with participation from PPP
Series B (2020): $18M led by Bruker Corporation, ND Capital, Trancos IONpath Investors, Vertical Venture Partners Growth Fund, Samsara BioCapital, Genoa Ventures, Norwich Ventures, and Paladin Partners Investments
Debt (2021): $1M supported by PPP
Key Investors in Ionpath
Norwich Ventures
Norwich Ventures is a specialized venture capital firm established in 2004, focusing on early-stage medtech investments. The firm seeks to support entrepreneurs developing innovative technologies that address significant unmet medical needs.
Samsara BioCapital
Samsara BioCapital is a venture firm dedicated to building and investing in transformative life science companies that address major medical challenges.
Genoa Ventures
Genoa Ventures is an investment firm focused on the intersection of biology and technology, supporting early-stage companies that drive innovation in the life sciences.
What's next for Ionpath?
With the recent infusion of capital, Ionpath is well-positioned to accelerate its commercial expansion and deepen its research capabilities. The company is expected to focus on scaling its MIBI platform to meet the growing demand for high-plex imaging in clinical and translational research settings. As the firm matures, strategic priorities will likely include the enhancement of its data analysis pipeline and the expansion of its footprint within the global immuno-oncology market. By maintaining its focus on high-resolution tissue analysis, Ionpath is set to remain a critical partner for organizations aiming to translate complex biological data into therapeutic breakthroughs.
See full Ionpath company page
